The discussion will cover fixed-duration treatments vs continuous therapy for CLL and provide a brief overview of venetoclax-based regimens approved for 12 cycles with obinutuzumab and 24 cycles with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results